The study, sponsored by Charles University, aims to evaluate the transition from an open-source automated insulin delivery system (AndroidAPS) to commercially available systems (Control-IQ and MiniMed 780G) in adults with Type 1 Diabetes. This research is significant as it addresses the growing market for advanced diabetes management technologies, particularly in the context of personalized medicine. The findings could influence market dynamics by providing comparative efficacy data that may affect clinician and patient preferences, potentially impacting sales of the involved commercial systems. The study's outcomes may also provide insights into the competitive landscape, highlighting the advantages of proprietary systems over open-source alternatives, which could have implications for future product development and marketing strategies.